BeOne Medicines
BeOne Medicines Sells IMDELLTRA® Ex-China Royalties to Royalty Pharma for $885M Upfront
In a strategic move, BeOne monetizes its ex-China royalty stream for the DLL3×CD3 bispecific IMDELLTRA®, freeing capital for its pipeline while retaining domestic commercialization rights.